Text size: S M L XL

SALOME Recruitment
Paused to Cope with
National Drug Shortage

VANCOUVER, March 12, 2012 — The BC government and the province's health authorities (including Providence Health Care) are working to mitigate a national shortage of Sandoz pharmaceutical products that include the hydromorphone (brand name Dilaudid) currently being used for SALOME.

Sandoz Canada is the sole Canadian supplier for the hydromorphone dosage needed for this study.

As a result of this drug shortage, recruitment for the trial has been paused until this supply issue can be resolved. We cannot say how long the delay will be, but we expect it will be at least two months.

There are currently 24 participants in the study receiving either injectable hydromorphone or diacetylmorphine, the active ingredient of heroin.

Half of the Current participants are double blinded to hydromorphone and the other half to diacetylmorphine.

Regardless of this process, we presently have enough supply and the current SALOME participants will continue to receive their study medication.

Once this supply issue is resolved, recruitment will continue. All current participants will remain in the study.

If you have any further questions or concerns, please contact Kurt Lock at klock@cheos.ubc.ca or 604-682-7518